MedTrace Logo

Sorafenib Study: Dosing in Patients With Pulmonary Arterial Hypertension (PAH)

NCT00452218 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2016-08-24

No results posted yet for this study

Summary

The purpose of this study is to assess the safety and tolerability of sorafenib in patients with PAH already on existing therapy with a prostacyclin \[epoprostenol (Flolan)\], treprostinil (Remodulin), or iloprost alone, or with or without sildenafil (Viagra/Revatio).

Conditions

Interventions

DRUG

Sorafenib

200 mg daily and dose escalated to a maximum of 400 mg twice daily

Sponsors & Collaborators

  • Bayer

    collaborator INDUSTRY

  • University of Chicago

    lead OTHER

Principal Investigators

  • Mardi Gomberg, M.D. · University of Chicago

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-03-31
Primary Completion
2012-05-31
Completion
2012-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00452218 on ClinicalTrials.gov